Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic approaches in Parkinson's disease and related disorders
Elvira Valera, Eliezer Masliah
Journal of Neurochemistry (2016) Vol. 139, Iss. S1, pp. 346-352
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
Fabrizio Chiti, Christopher M. Dobson
Annual Review of Biochemistry (2017) Vol. 86, Iss. 1, pp. 27-68
Closed Access | Times Cited: 2326
Resveratrol alleviates MPTP‐induced motor impairments and pathological changes by autophagic degradation of α‐synuclein via SIRT1‐deacetylated LC3
Yanjie Guo, Su‐Yan Dong, Xin‐Xin Cui, et al.
Molecular Nutrition & Food Research (2016) Vol. 60, Iss. 10, pp. 2161-2175
Open Access | Times Cited: 158
Dopamine D2 receptor restricts astrocytic NLRP3 inflammasome activation via enhancing the interaction of β-arrestin2 and NLRP3
Jialei Zhu, Zhaoli Hu, Xiaojuan Han, et al.
Cell Death and Differentiation (2018) Vol. 25, Iss. 11, pp. 2037-2049
Open Access | Times Cited: 137
Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease
Kai Zhang, Shiou Zhu, Jiamei Li, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 11, Iss. 10, pp. 3015-3034
Open Access | Times Cited: 92
Observation of an α-synuclein liquid droplet state and its maturation into Lewy body-like assemblies
Maarten C. Hardenberg, Tessa Sinnige, Sam Casford, et al.
Journal of Molecular Cell Biology (2020)
Open Access | Times Cited: 89
Modulation of Amyloid States by Molecular Chaperones
Anne S. Wentink, Carmen Nussbaum‐Krammer, Bernd Bukau
Cold Spring Harbor Perspectives in Biology (2019) Vol. 11, Iss. 7, pp. a033969-a033969
Open Access | Times Cited: 79
Mechanisms of enhanced aggregation and fibril formation of Parkinson’s disease-related variants of α-synuclein
Takashi Ohgita, Norihiro Namba, Hiroki Kono, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 39
Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders
Zi-Hua Guo, Saadullah Khattak, Mohd Ahmar Rauf, et al.
Molecules (2023) Vol. 28, Iss. 3, pp. 1283-1283
Open Access | Times Cited: 27
Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy
Omar M. A. El‐Agnaf, Cassia Overk, Edward Rockenstein, et al.
Neurobiology of Disease (2017) Vol. 104, pp. 85-96
Open Access | Times Cited: 73
Mitochondrial function and autophagy: integrating proteotoxic, redox, and metabolic stress in Parkinson's disease
Jianhua Zhang, Matilda L. Culp, Jason Craver, et al.
Journal of Neurochemistry (2018) Vol. 144, Iss. 6, pp. 691-709
Open Access | Times Cited: 62
Nanomedicine-based immunotherapy for central nervous system disorders
Sumaira Hanif, Pir Muhammad, Rose Chesworth, et al.
Acta Pharmacologica Sinica (2020) Vol. 41, Iss. 7, pp. 936-953
Open Access | Times Cited: 51
α-Synuclein disrupts the anti-inflammatory role of Drd2 via interfering β-arrestin2-TAB1 interaction in astrocytes
Ren‐Hong Du, Yan Zhou, Meiling Xia, et al.
Journal of Neuroinflammation (2018) Vol. 15, Iss. 1
Open Access | Times Cited: 47
Neuroprotective Effect of Echinacoside in Subacute Mouse Model of Parkinson’s Disease
Yan Liang, Chang Chen, Baomei Xia, et al.
BioMed Research International (2019) Vol. 2019, pp. 1-8
Open Access | Times Cited: 45
Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies
Edward Rockenstein, Gary R. Ostroff, Fusun Dikengil, et al.
Journal of Neuroscience (2017) Vol. 38, Iss. 4, pp. 1000-1014
Open Access | Times Cited: 46
GPER Agonist G1 Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson Disease
Jing Guan, Beibei Yang, Yi Fan, et al.
NeuroImmunoModulation (2017) Vol. 24, Iss. 1, pp. 60-66
Closed Access | Times Cited: 46
The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease
Diane Stephenson, David Hill, Jesse M. Cedarbaum, et al.
Journal of Parkinson s Disease (2019) Vol. 9, Iss. 3, pp. 553-563
Open Access | Times Cited: 38
Screening of small molecules using the inhibition of oligomer formation in α-synuclein aggregation as a selection parameter
Roxine Staats, Thomas C. T. Michaels, Patrick Flagmeier, et al.
Communications Chemistry (2020) Vol. 3, Iss. 1
Open Access | Times Cited: 36
Histone Deacetylases as Epigenetic Targets for Treating Parkinson’s Disease
Yan Li, Zhicheng Gu, Shuxian Lin, et al.
Brain Sciences (2022) Vol. 12, Iss. 5, pp. 672-672
Open Access | Times Cited: 22
Iron Oxide Nanoparticles Application in Toxicity Therapeutics of CNS Disorders Indicated by Molecular MRI
Lei Zhao, Tao Peng, Shawn Wu
IntechOpen eBooks (2025)
Closed Access
Signature of Aberrantly Expressed microRNAs in the Striatum of Rotenone-Induced Parkinsonian Rats
Camila Hillesheim Horst, Franciele Schlemmer, Natália de Aguiar Montenegro, et al.
Neurochemical Research (2018) Vol. 43, Iss. 11, pp. 2132-2140
Closed Access | Times Cited: 37
Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease
Brian Spencer, Ivy Trinh, Edward Rockenstein, et al.
Neurobiology of Disease (2019) Vol. 127, pp. 163-177
Open Access | Times Cited: 35
Inhibition of α‐Synuclein Amyloid Fibril Elongation by Blocking Fibril Ends
Volodymyr V. Shvadchak, Kseniia Afitska, Dmytro A. Yushchenko
Angewandte Chemie International Edition (2018) Vol. 57, Iss. 20, pp. 5690-5694
Closed Access | Times Cited: 34
Development of immunotherapy and nanoparticles-based strategies for the treatment of Parkinson’s disease
Ramesh Duwa, Jee‐Heon Jeong, Simmyung Yook
Journal of Pharmaceutical Investigation (2021) Vol. 51, Iss. 4, pp. 465-481
Closed Access | Times Cited: 23
α-Synuclein oligomers and fibrils: partners in crime in synucleinopathies
Alessandra Bigi, Roberta Cascella, Cristina Cecchi
Neural Regeneration Research (2023) Vol. 18, Iss. 11, pp. 2332-2342
Open Access | Times Cited: 8
D-512, a novel dopamine D2/3receptor agonist, demonstrates greater anti-Parkinsonian efficacy than ropinirole in Parkinsonian rats
David Lindenbach, Banibrata Das, Melissa M. Conti, et al.
British Journal of Pharmacology (2017) Vol. 174, Iss. 18, pp. 3058-3071
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top